Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 8, 2011, Pages 750-760

  Maae, Else ^a,b   Nielsen, Martin ^a   Steffensen, Karina D ^a   Jakobsen, Erik H ^a   Jakobsen, Anders ^a   Sørensen, Flemming B ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Automated quantification; Breast cancer; Flt 1; Image analysis; Immunohistochemistry; Reproducibility; VEGF A; VEGF B; VEGFR 1

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1;

ARTICLE; AUTOMATION; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCORING SYSTEM; TISSUE SECTION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; REPRODUCIBILITY OF RESULTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 80051725152     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411412599     Document Type: Article

References (34)

1. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, et al. 2000. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 60:2898-2905.
2. Allred DC, Harvey JM, Berardo M, Clark GM. 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155-168.
3. Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A, Riggins G, Anderson S, Vredenburgh J, et al. 2004. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res. 10:4083-4088.
4. Bluff JE, Menakuru SR, Cross SS, Higham SE, Balasubramanian SP, Brown NJ, Reed MW, Staton CA. 2009. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer. 101:666-672.
5. Brey EM, Lalani Z, Johnston C, Wong M, McIntire LV, Duke PJ, Patrick CW, Jr. 2003. Automated selection of DAB-labeled tissue for immunohistochemical quantification. J Histochem Cytochem. 51:575-584.
6. Callagy G, Dimitriadis E, Harmey J, Bouchier-Hayes D, Leader M, Kay E. 2000. Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer: a more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Appl Immunohistochem Mol Morphol. 8:104-109.
7. Carpenter PM, Chen WP, Mendez A, McLaren CE, Su MY. 2009. Angiogenesis in the progression of breast ductal proliferations. Int J Surg Pathol April 29, DOI: 10.1177/1066896909333511. http://ijs.sagepub.com/content/early/2009/04/29/1066896909333511.
8. Carrillo de Santa PE, Arias FC, Caso PE, Munoz Molina GM, Sanchez HI, Muguruza TI, Moreno BR, Sacristan LS, Gomez PA, del Val Toledo LM. 2009. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer. 115:1701-1712.
9. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. 2010. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem 58:95-107.
10. Dvorak HF, Brown LF, Detmar M, Dvorak AM. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1029-1039.
11. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med. 9:669-676.
12. Fischer C, Mazzone M, Jonckx B, Carmeliet P. 2008. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 8:942-956.
13. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182-1186.
14. Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. 2008. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol. 39:1835-1843.
15. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB. 2001. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol. 193:325-332.
16. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A. 2008. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest. 26:1024-1031.
17. Li X, Lee C, Tang Z, Zhang F, Arjunan P, Li Y, Hou X, Kumar A, Dong L. 2009. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr. 3:322-327.
18. MacQueen J. 1967. Some methods for classification and analysis of multivariate observations. In: Proceedings of the fifth Berkeley symposium on mathematical statistics and probability. Volume 1. Berkeley, CA: University of California Press. p. 281-297.
19. Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, Giannopoulou I. 2008. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res. 10:R49.
20. Montironi R, Diamanti L, Thompson D, Bartels HG, Bartels PH. 1996. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol. 30:191-200.
21. Mylona E, Alexandrou P, Giannopoulou I, Liapis G, Sofia M, Keramopoulos A, Nakopoulou L. 2007. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol. 104:557-563.
22. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. 2007. Prognostic analysis of tumor angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 97:391-397.
23. Perrone G, Santini D, Vincenzi B, Zagami M, La CA, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, et al. 2005. COX-2 expression in DCIS: correlation with VEGF, HER-2/ neu, prognostic molecular markers and clinicopathological features. Histopathology. 46:561-568.
24. Ribeiro-Silva A, Ribeiro DV, Zucoloto S. 2006. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol. 125:512-518.
25. Ruifrok AC, Johnston DA. 2001. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 23:291-2993.
26. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. 2003. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat. 82:147-154.
27. Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE, Landberg G. 2005. Tumorspecific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol. 23:4695-4704.
28. Safwat MD, Habib F, Elayat A, Oweiss N, Reffat S, Algaidi S. 2009. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast. Folia Morphol (Warsz). 68:144-155.
29. Schmidt M, Voelker HU, Kapp M, Dietl J, Kammerer U. 2008. Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumor stage. Anticancer Res. 28:1719-1724.
30. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, et al. 2008. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 26:4672-4678.
31. Seidal T, Balaton AJ, Battifora H. 2001. Interpretation and quantification of immunostains. Am J Surg Pathol. 25:1204-1207.
32. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H. 2004. Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol. 40:13-20.
33. Smejkal GB, Shainoff JR. 1997. Enhanced digital imaging of diaminobenzidine -stained immunoblots. Biotechniques. 22:462.
34. Zhou S, Wang GP, Liu C, Zhou M. 2006. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer. 6:231.